Reborn Redx Inks Global Licensing Deal With AstraZeneca

AZ Buys Rights To Porcupine Inhibitor For Fibrotic Diseases

 
• By Sten Stovall

AstraZeneca will take Redx's RXC006 into clinical development, targeting fibrotic diseases, giving valuable credibility to the biotech’s Wnt pathway hypothesis. 

Signpost
Redx Has Come A Long Way Since Exiting Insolvency In 2017 • Source: Shutterstock

More from Deals

More from Business